Journals / Cukurova Medical Journal / 2021 / Cilt: 46 - Sayı: 1

The relationship between oral and periodontal findings with disease type in scleroderma patients

Skleroderma hastalarının ağız ve periodontal bulguları ile hastalık tutulumları arasındaki ilişki

Pages
39–45
Publication Date
2021-03-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are needed to evaluate the relationship between SD types and periodontal diseases in terms of etiology and pathogenesis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of this study is to determine the maximum mouth opening and periodontal findings of scleroderma (SD) patients and to evaluate the relationship of these findings with the subgroups of the disease.
📊
Key Findings & Data:Materials and Methods: Seventy-four adults (60 females, 14 males) with scleroderma were included in this study.
💡
Conclusion & Impact:Further studies are needed to evaluate the relationship between SD types and periodontal diseases in terms of etiology and pathogenesis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:scleroderma · periodontal disease · mouth opening

Abstract

Purpose: The aim of this study is to determine the maximum mouth opening and periodontal findings of scleroderma (SD) patients and to evaluate the relationship of these findings with the subgroups of the disease. Materials and Methods: Seventy-four adults (60 females, 14 males) with scleroderma were included in this study. Study groups were determined according to the type of scleroderma (51 Diffuse, 23 localized). Clinical periodontal parameters (gingival index, plaque index and periodontal pocket depth) of the patients were recorded. Maximum mouth opening and saliva amount were determined. Temporomandibular joint examination was performed. Results: The mean mouth opening in patients with SD was 36.6 ± 8.0 mm. A statistically significant difference was found between the mean mouth opening of the diffuse type SD patients (33.7 ± 7.3 mm) compared to the localized type SD patients (43.0 ± 5.4 mm). In diffuse type SD patients, the mean pocket depth (3.17 ± 0.9) was statistically significantly higher than in localized type SD patients (2.69 ± 0.6). Conclusion: Scleroderma may cause various oral problems due to its wide range of limited mouth opening and its effect on periodontal tissues. Mouth opening exercises and regular dentist check-ups may be recommended in the treatment of oral problems in SD patients. Further studies are needed to evaluate the relationship between SD types and periodontal diseases in terms of etiology and pathogenesis.

Özet

Amaç: Bu çalışmanın amacı, skleroderma (SD) hastalarının mevcut ağız açıklığını ve periodontal bulgularını tespit etmek ve bu bulgular ile hastalığın alt grupları arasındaki ilişkiyi değerlendirmektir. Gereç ve Yöntem: Çalışmaya 74 yetişkin (60 kadın, 14 erkek) skleroderma hastası dahil edildi. Çalışma grupları skleroderma tipine (51 Diffüz, 23 lokalize) göre belirlendi. Çalışmaya katılan hastaların klinik periodontal parametreleri (Gingival indeks, plak indeksi ve cep derinliği) kaydedildi. Maksimum ağız açıklığı ve tükürük miktarı belirlendi. Temporamandibular eklem muayenesi yapıldı. Bulgular: Skleroderma hastalarında ortalama ağız açıklığı 36,6±8,0 mm tespit edildi. Diffüz tip SD hastalarının ortalama ağız açıklığı (33,7±7,3 mm) ve lokalize tip SD hastalarının ağız açıklığı (43,0±5,4 mm) arasında istatistiksel olarak anlamlı bir fark bulundu. Diffüz tip SD hastalarında cep ortalama cep derinliğinin (3,17±0,9), lokalize tip SD hastalarına (2,69±0,6) göre istatistiksel anlamlı düzeyde yüksek olduğu tespit edildi. Sonuç: Sklorederma yaygın olarak sınırlı ağız açıklığına ve periodontal dokulara etkisi nedeniyle çeşitli oral problemlere yol açabilir. SD hastalarının oral problemlerinin tedavisinde, ağız açma egzersizleri ve düzenli diş hekimi kontrolü önerilebilir. Ayrıca SD tipleri ile periodontal hastalıklar arasındaki ilişkinin etiyolojisi ve patogenezini değerlendiren ileriki çalışmalara ihtiyaç bulunmaktadır.

🔖

Cite This Article

ÖZCAN, M., CİFTCİ, V., TÜRK, İ. (2021). The relationship between oral and periodontal findings with disease type in scleroderma patients. Cukurova Medical Journal, Cilt: 46 - Sayı: 1, 39–45. https://ajindex.com/articles/115014

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69:1809-15
  2. Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev. 2003;2:181-91
  3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger Jr et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202-5
  4. Masi AT, Diagnostic SFSCotARA, Committee TC. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581-90
  5. Walker U, Tyndall A, Czirjak L, Denton C, FargeBancel D, Kowal-Bielecka O et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007;66:754-63
  6. Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37:223-235
  7. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol. 2012;24:165-70
  8. Kwakkenbos L, Jewett LR, Baron M, Bartlett SJ, Furst D, Gottesman K et al. The Scleroderma Patientcentered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. BMJ open. 2013;3(8)
  9. Almeida C, Almeida I, Vasconcelos C. Quality of life in systemic sclerosis. Autoimmun Rev. 2015;14:1087- 96
  10. Veale B, Jablonski R, Frech T, Pauling J. Orofacial manifestations of systemic sclerosis. Br Dent J. 2016;221:305-10
  11. Vincent C, Agard C, Barbarot S, N'guyen J, Planchon B, Durant C et al. Orofacial manifestations of systemic sclerosis: a study of 30 consecutive patients. Rev Stomatol Chir Maxillofac Chir Orale. 2010;111:128-34
  12. Jung S, Martin T, Schmittbuhl M, Huck O. The spectrum of orofacial manifestations in systemic sclerosis: a challenging management. Oral Dis. 2017;23:424-39
  13. Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum